Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2004

01.07.2004 | Original Article

Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model

verfasst von: O. Glehen, O. A. Stuart, F. Mohamed, P. H. Sugarbaker

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Peritoneal surface malignancy is a common manifestation of failure of treatment for abdominal cancers. Best results of treatment have been achieved with complete cytoreduction followed by heated intraoperative chemotherapy. Melphalan is a chemotherapeutic agent that shows increased pharmacological activity with heat. But the combination of intraperitoneal administration and heat have never been tested for this drug. The purpose of this study was to evaluate the effect of hyperthermia on the pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rodent model.

Methods

Melphalan was given by the intraperitoneal route to 20 Sprague-Dawley rats at a dose of 12 mg/kg over 90 min. Rats were randomized into two groups according to the temperature of the peritoneal perfusate: group NT received normothermic (33.5°C) melphalan; group HT received hyperthermic (42°C) melphalan. During the course of intraperitoneal chemotherapy, peritoneal fluid and blood were sampled at 5, 15, 30, 60 and 90 min. At the end of procedure, the rats were killed and tissues samples (heart, liver, ileum, jejunum, colon, omentum, and abdominal wall) were collected. Concentrations of melphalan were determined in peritoneal fluid, plasma, and tissues by high-performance liquid chromatography.

Results

The area under the curve (AUC) of peritoneal fluid melphalan was significantly lower in the HT group than in the NT group (P=0.001), whereas no significant difference in plasma AUC was found. AUC ratios (AUC peritoneal fluid/AUC plasma) were 12.1 for the NT group and 12.3 for the HT group. The mean time to reach the plasma peak was shorter in the HT group than in the NT group (P=0.004). The HT group exhibited increased melphalan concentrations in all intraabdominal tissues. These differences were significant for the ileum (P=0.03) and jejunum (P=0.04).

Conclusion

Hyperthermia affected the pharmacokinetics of intraperitoneal melphalan by decreasing the AUC of peritoneal fluid melphalan without increasing the plasma AUC. It increased intraabdominal tissue concentrations.
Literatur
1.
Zurück zum Zitat Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165PubMed Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165PubMed
2.
Zurück zum Zitat Daly JM, Wang YM, Kapelanski D, Frazier OH (1984) Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. J Surg Res 37:343PubMed Daly JM, Wang YM, Kapelanski D, Frazier OH (1984) Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. J Surg Res 37:343PubMed
3.
Zurück zum Zitat Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1PubMed Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1PubMed
4.
Zurück zum Zitat Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M (2001) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 87:120PubMed Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M (2001) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 87:120PubMed
5.
Zurück zum Zitat Dewhirst M, Gross JF, Sim D, Arnold P, Boyer D (1984) The effect of rate of heating or cooling prior to heating on tumor and normal tissue microcirculatory blood flow. Biorheology 21:539PubMed Dewhirst M, Gross JF, Sim D, Arnold P, Boyer D (1984) The effect of rate of heating or cooling prior to heating on tumor and normal tissue microcirculatory blood flow. Biorheology 21:539PubMed
6.
Zurück zum Zitat Elias D, Pocard M (2003) Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Clin North Am 12:543 Elias D, Pocard M (2003) Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Clin North Am 12:543
7.
Zurück zum Zitat Glehen O, Beaujard AC, Arvieux C, Huber O, Gilly FN (2002) Les carcinoses péritonéales. Traitement chirurgical, péritonectomies et chimiohyperthermie intrapéritonéale. Gastroenterol Clin Biol 26:210PubMed Glehen O, Beaujard AC, Arvieux C, Huber O, Gilly FN (2002) Les carcinoses péritonéales. Traitement chirurgical, péritonectomies et chimiohyperthermie intrapéritonéale. Gastroenterol Clin Biol 26:210PubMed
8.
Zurück zum Zitat Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21:799CrossRefPubMed Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21:799CrossRefPubMed
9.
Zurück zum Zitat Gutman M, Sofer D, Lev-Chelouche D, Merimsky O, Klausner JM (1997) Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. Invasion Metastasis 17:169PubMed Gutman M, Sofer D, Lev-Chelouche D, Merimsky O, Klausner JM (1997) Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. Invasion Metastasis 17:169PubMed
10.
Zurück zum Zitat Hahn GM, Strande DP (1976) Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst 57:1063PubMed Hahn GM, Strande DP (1976) Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst 57:1063PubMed
11.
Zurück zum Zitat Howell SB, Pfeifle CE, Olshen RA (1984) Intraperitoneal chemotherapy with melphalan. Ann Intern Med 101:14PubMed Howell SB, Pfeifle CE, Olshen RA (1984) Intraperitoneal chemotherapy with melphalan. Ann Intern Med 101:14PubMed
12.
Zurück zum Zitat Jacquet P, Detroz B (1991) Intraperitoneal hyperthermia, a rat model. Acta Gastroenterol Belg 54:A84 Jacquet P, Detroz B (1991) Intraperitoneal hyperthermia, a rat model. Acta Gastroenterol Belg 54:A84
13.
Zurück zum Zitat Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH (1998) Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41:147CrossRefPubMed Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH (1998) Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41:147CrossRefPubMed
14.
Zurück zum Zitat Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y (1984) Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 44:1840PubMed Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y (1984) Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 44:1840PubMed
15.
Zurück zum Zitat Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16:2906PubMed Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16:2906PubMed
16.
Zurück zum Zitat Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ (1998) Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 14:202CrossRefPubMed Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ (1998) Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 14:202CrossRefPubMed
17.
Zurück zum Zitat Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH (2003) Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 10:463CrossRefPubMed Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH (2003) Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 10:463CrossRefPubMed
18.
Zurück zum Zitat Norda A, Loos U, Sastry M, Goehl J, Hohenberger W (1999) Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 43:35CrossRefPubMed Norda A, Loos U, Sastry M, Goehl J, Hohenberger W (1999) Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 43:35CrossRefPubMed
19.
Zurück zum Zitat Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr, Kapp DS (1988) Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 11:368PubMed Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr, Kapp DS (1988) Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 11:368PubMed
20.
Zurück zum Zitat Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH (2001) Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 76:106CrossRefPubMed Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH (2001) Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 76:106CrossRefPubMed
21.
Zurück zum Zitat Riviere JE, Page RL, Aucoin DP, Rogers RA, Williams PL (1991) Effect of hyperthermia on the in vitro hydrolysis of melphalan. Int J Hyperthermia 7:527PubMed Riviere JE, Page RL, Aucoin DP, Rogers RA, Williams PL (1991) Effect of hyperthermia on the in vitro hydrolysis of melphalan. Int J Hyperthermia 7:527PubMed
22.
Zurück zum Zitat Sarosy G, Leyland-Jones B, Soochan P, Cheson BD (1988) The systemic administration of intravenous melphalan. J Clin Oncol 6:1768PubMed Sarosy G, Leyland-Jones B, Soochan P, Cheson BD (1988) The systemic administration of intravenous melphalan. J Clin Oncol 6:1768PubMed
23.
Zurück zum Zitat Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, McQuellon R, Geisinger KR, Loggie BW (2003) Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138:26PubMed Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, McQuellon R, Geisinger KR, Loggie BW (2003) Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138:26PubMed
24.
Zurück zum Zitat Shiu MH, Fortner JG (1980) Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res 40:4081PubMed Shiu MH, Fortner JG (1980) Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res 40:4081PubMed
25.
Zurück zum Zitat Sugarbaker PH (2001) Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 27:239CrossRefPubMed Sugarbaker PH (2001) Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 27:239CrossRefPubMed
26.
Zurück zum Zitat Urano M, Ling CC (2002) Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 18:307CrossRefPubMed Urano M, Ling CC (2002) Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 18:307CrossRefPubMed
27.
Zurück zum Zitat Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15:79CrossRefPubMed Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15:79CrossRefPubMed
Metadaten
Titel
Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model
verfasst von
O. Glehen
O. A. Stuart
F. Mohamed
P. H. Sugarbaker
Publikationsdatum
01.07.2004
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0779-0

Weitere Artikel der Ausgabe 1/2004

Cancer Chemotherapy and Pharmacology 1/2004 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.